Stories related to Science

Women’s health

No matter what stage of life or part of the world a woman is in, knowledge is power.

Sustainability at Roche: Our impact

Engaging with stakeholders is crucial to create sustainable value. Stakeholder engagement enables us to jointly develop solutions.

Roche at RCOG

The annual Royal College of Obstetrics and Gynaecology (RCOG) World Congress brings together health professionals to learn from each other and exchange views.

The NT-proBNP Story

Biomarkers play a crucial role in Roche’s commitment to personalised healthcare. To find them, we rely on the promising research of our external partners.

Better together: Helping one million people with diabetes

Ask anybody with diabetes: managing it is time consuming, exhausting and very annoying.

Of bonds and benefits

Two made-in-Japan collaborations strengthen both Roche and its partners.

Pioneering a new era in cancer diagnostics

Effective therapies start with an accurate diagnosis. Diagnostics advancements are helping patients to receive personalised treatments.

Bringing patient support to a rare disease

Learn how we are breaking down barriers that prevent patients from joining clinical trials for spinal muscular atrophy.

Women’s health at every stage of life

Every woman’s journey through life is her own, yet all face similar choices and challenges. Health is critical at every stage of this journey.

Roche on World Cancer Day

We are happy to join the global cancer community on this important day to unite behind a shared goal: to end cancer.

Our Approach to Cancer Immunotherapy

Roche are leading in cancer immunotherapy through innovative research, including immune profiling, with the goal to develop treatment tailored to individuals.

Partnering in a digital era

Collaborations between healthcare and technology companies are driving the future of healthcare

Unconventional wisdom

How challenging the status quo led to the discovery of the B cell as a new target in MS.

Roche at J.P. Morgan Healthcare Conference

Collaborating to drive the future of personalised healthcare

What is PHC?

Personalised healthcare is about providing the right treatment for the right patient. Fitting treatments to patients has always been the objective of medicine, of course. But only recent advances in science and technology have made this possible.

Always trying to err on the side of drug safety

Keeping its medicines safe for the people who need them is at the core of our remit.

How decades of blood cancer research is paying off

We explore how a growing understanding of the biology of blood cancers is transforming the development and delivery of treatments for patients.

Rising to the challenge

As multidrug resistant strains of bacteria are posing a growing threat to human health worldwide, our scientists are working hard on the next generation of antibiotics and diagnostic tests.

The value of diagnostics in heart failure management

Heart failure affects millions of people and despite improvement in care, management remains challenging. Biomarkers can help patients at every stage of care.

Every person is unique. So is every cancer.

Advances in genomics are helping physicians to understand patients’ unique cancer types and to identify whether targeted therapy options are available for them.

Science and the City: Munich

Munich may be known as a world cultural city, but it also now a driving force in driving innovation in healthcare.

Changing the perspective on lung cancer: a story of hope and survival

How does understanding each lung cancer’s unique footprint set you on the right path for a promising new future? Find out...

The many faces of breast cancer

Each women is unique. But breast cancer doesn’t care. It can happen to anyone. And when it does happen, each woman’s breast cancer is as individual as she is.

Busting myths in lung cancer

How much do you really know about lung cancer? Our interactive flashcards bust some common myths about lung cancer.

Shedding light on progression in MS

How Roche is paving the way for better understanding of MS disease progression and monitoring.

Expecting more for people with PPMS

Dr. Jerome de Seze, explains how recent clinical advances mean more and more people are being diagnosed with PPMS.

MS measurements explained

How we define the ways in which multiple sclerosis can be measured.

Primary progressive MS: Different perspectives

Dr. de Seze and Craig Milverton, who lives with primary progressive multiple sclerosis (PPMS), share their experiences managing and living with this form of MS.

Roche at the World Congress on Lung Cancer

Check out how we are transforming the diagnosis and management of lung cancer.

Keeping every drop safe

Screening tests protect blood supplies from contamination by the Zika virus.

A future in mind – rising to the challenge of Alzheimer’s

Discover how we are advancing towards treatments that can stop, slow or prevent, and ultimately improve the care available for people with Alzheimer’s disease.

Science and the City: Basel

Basel grew up with the chemical-pharmaceutical industry, and the chemical-pharmaceutical industry grew up with Basel.

Be part of Science and the City in Basel

Watch Nobel Prize winner Paul Nurse and Roche scientist Bryn Roberts on our live streaming. Get more information here.

Roche at ESMO

Learn about how we are leading the science of cancer to improve outcomes for patients today and tomorrow.

What is Life?- Live Streaming with Paul Nurse.

Watch the live stream of Nobel Prize winner Sir Paul Nurse

The realities of pursuing the cure for cancer

Cindy Perettie, our Global Head of Oncology Strategy, provides her personal perspective on the challenges of leading the cure for cancer.

Forms of multiple sclerosis: What are the similarities and differences?

The underlying biology of multiple sclerosis is similar for everyone, but its course and symptoms vary from person to person. Explore the similarities and differences between two forms of MS.

Lymphoma: Know the facts

Lymphoma is one of the most prevalent forms of blood cancer. Click on our interactive flashcards to find out some key facts on lymphoma we all should know.

Cancer immunotherapy biomarkers

Biomarkers continue to play a critical role in the development of personalised healthcare, particularly in cancer.

Smart technology speeds up development of antibiotics

Roche and British biotechnology company Discuva are collaborating to develop new classes of antibiotics for the treatment of multidrug-resistant bacteria.

Heart failure: the role of biomarkers in disease management

Heart failure can have a great impact on people’s live. Biomarkers can support physicians to make informed decisions as to the best course of care to patients.

Fighting viral hepatitis

Despite the burden it places on communities across the world, hepatitis appears to have been largely ignored as a public health concern

A little-known virus that can cause big problems

Most people can spend their entire lives not knowing they’ve been infected with CMV. But for transplant patients, this quiet invader can be life-threatening

Roche in Haemophilia

Find out more about haemophilia A and how Roche is developing novel approaches to hopefully advance the management of this serious disorder.

Improving outcomes for people with multiple sclerosis

The London School of Economics “International MultiPlE Sclerosis Study” explores the need for policy change and better outcomes for people with MS.

Future of immunology: It’s all about balance

David M. Lee, Head of Immunology, Inflammation and Infectious Diseases, shares personal experience as a physician and talks about new treatment approaches for immune-mediated diseases.

‘Accelerators and brakes’ to restore immune balance

Roche strategy in Immunology is to make use of the growing scientific understanding of immune pathways and to selectively manipulate these in order to restore immune balance.

EuroMedLab 2017: transforming laboratory science

Held every two years, EuroMedLab is one of the most influential in vitro diagnostics events worldwide.

Roche at ASCO

At this year’s Annual Meeting, we are demonstrating in many ways how we are helping make a difference in cancer care.

Meet Cordula

Roche as an employer is providing a truly people-focused working environment. I will never forget how impressed I was when I joined Roche and became aware of the passion and engagement in the work of each and every colleague.

From “magic bullets” to new generation antibodies

With today's health challenges, medical progress is more important than ever. Therapeutic antibodies are addressing the complexity of targeting diseases with unmet medical need.

The role of HPV in cervical cancer

Everything you need to know about HPV infections and the link between HPV and cervical cancer.

What is multiple sclerosis?

MS is usually thought of as a single disease, but its course and symptoms vary from person to person.

Fighting antimicrobial resistance with diagnostics

Antimicrobial resistance is a global and continuously raising global health challenge. Here’s what we are doing to address this problem.

Facts about bladder cancer

Bladder cancer is one of the top ten most common cancers in the world.

Beyond the immunity cycle

Roche’s scientists are leading pioneers in immune biology and cancer research, which is resulting in innovative and personalised treatment options in cancer.

Lung cancer

Approximately 1.8 million people develop lung cancer every year. Can new diagnostic tools deliver earlier diagnosis and smarter treatment choices?

Roche in neuroscience

Roche Neuroscience addresses areas of high unmet medical need with no approved, effective or safe medicines. Learn about our approach.

Our response to cancer always starts with the science

Targeting cancer demands a deep understanding of its complexities. Our researchers have the freedom to explore cutting-edge science & technology to achieve this.

Organs-on-a-Chip technology

Tiny labs made of plastic simulate the human body- the Organs-on-a-Chip technology shows new approaches to obtain human-relevant information on a potential drug.

Creating value through partnerships

Partnering builds on our culture, one in which we listen to a potential partner and structure a collaboration that meets both parties’ needs.

Fierce Women in Biopharma 2016

Among the 16 women who have been named by Fierce Pharma as the most important female leaders in the healthcare sector in 2016 are two from our company.

Ovarian cancer treatment advances over time – what’s next?

Take a look at the advances in ovarian cancer treatment over time and what the future holds for women with this disease.

Roche at the American Society of Hematology Annual Meeting

We presented new data on medicines for various blood cancers and blood disorders at the 2016 American Society of Hematology Annual Meeting.

The role of companion diagnostics in breast cancer

The right treatment decision is essential for a breast cancer patient’s well-being.

Spotlight on comprehensive genomic profiling

Comprehensive genomic profiling provides valuable information that can help determine the best possible treatment for each patient.

Securing safe blood supplies in the face of the Zika virus international health emergency

Securing safe blood supplies in the face of the Zika virus international health emergency

Launch of new Investigator Initiated Studies Portal

The new Investigator Initiated Studies Portal offers a single point of entry for IIS submissions via the web.

Cancer immunotherapy

As our understanding of the immune system and tumour biology expands, so does our hope for developing treatments that may change people’s live.

Discover history’s most popular poster and its impact on how we see the world

The chart measuring visual acuity is the most popular poster in history.

New approaches to understand multiple sclerosis

MS is a disease of the central nervous system, estimated to affect 2.3 million people worldwide.

The complexities of lymphoma: The importance of subtypes

With more than 60 subtypes, non-Hodgkin lymphoma is a complex group of diseases. Read this article to learn more.

Roche at EURETINA 2016

EURETINA brings together specialists and experts of the ophthalmology community.

Making a difference in neuroscience

Gain insights on developing medicines with the potential to transform people’s lives.

Haematology

Haematology is a branch of medicine that deals with diseases of the blood. It is a complex, disparate and challenging area of medicine.

Roche at AACR 2016

The AACR Annual Meeting is an important event for cancer researchers and the broader cancer community.

Light bulb moments in MS

A journey of discovery and diagnosis; looking back at the history of multiple sclerosis

A new era in cancer diagnostics: a personal perspective

Dr Walter Koch, Head of Research at Roche Molecular Diagnostics, explains how his “dream job” is helping push into new frontiers of science.

Cervical cancer is preventable

Cervical cancer is preventable thanks to screening and vaccination programmes.

Information that carries hope for cancer patients

The partnership between Roche and Foundation Medicine, Inc. heralds a new chapter in the use of molecular information to choose the right treatments for cancer patients

Better screening for cervical cancer

Screening dramatically reduces the incidence and mortality of cervical cancer worldwide.

Milestone for testing future clinical trials in Autism Spectrum Disorder

Autism Spectrum Disorder (ASD) is one of the most common neurodevelopmental disorders, affecting approximately one in 68 children.

Computer simulations offer great promise in drug development

Giving lung cancer patients better options

An innovative blood test known as a liquid biopsy could spare lung cancer patients from the ordeal of surgical biopsies.

Keeping cancer immunotherapy personal

Fighting cancer using patients own immune system is a concept that has been around for a long time, and real advances in our understanding about how to do this have been made over the last 10-15 years.

Roche: bringing oncology innovation to light

Advances in our knowledge of molecular biology and new technologies could redefine approaches to scientific research and individualised patient care for cancer. However, the complexity of treating this disease will grow in tandem. Here we describe the challenges we face and some of the approaches we are adopting to overcome them.

Clinical trials

Clinical trials are essential to providing the scientific data required to determine whether new drugs, diagnostics or procedures are both safe and effective when used to diagnose and treat people.

Light bulb moments in oncology

15 of the biggest advances in cancer treatment to date.

Roche brings together 100 pioneers in an exciting new area of research

A select group of top scientists and researchers will meet to share their expertise in quantitative systems pharmacology.

Excellence in science

In our pursuit of excellence in science, our distinctiveness rests on four key elements: an exceptionally broad and deep understanding of molecular biology, the seamless integration of our pharmaceuticals and diagnostics capabilities, a diversity of approaches to maximise innovation, and a long-term orientation.

Digital biomarkers

Roche is pioneering this new way of measuring symptoms with apps deployed on smartphones.

9 things you may not know about cancer

Interesting facts about the world’s biggest health challenge.

Roche develops app to improve doctor-patient interaction

It is a sign of the times. Two Roche colleagues working out of Lebanon have developed an app that helps doctors communicate better with their patients.

Roche at EULAR 2015

Egyptian medical books have been found that reference swollen, painful joints. But RA, like many other autoimmune diseases, is still not fully understood.

Turning the page: Advances in MS clinical practice

Paulo Fontoura, MD, PhD, Global Head Clinical Development, Neuroscience, reflects on unique patient stories and shifting clinical practice

Roche at the American Society of Clinical Oncology Annual Meeting

Roche once again has a major presence at this years ASCO Annual Meeting, while also looking to the science and technologies that will hopefully bring us tomorrow's new therapeutic approaches

Roche: bringing oncology innovation to light

Advances in our knowledge of molecular biology and new technologies could redefine approaches to scientific research and individualised patient care for cancer. However, the complexity of treating this disease will grow in tandem. Here we describe the challenges we face and some of the approaches we are adopting to overcome them.

Roche at the American Association for Cancer Research

If cancer is cancer, why don’t we have a single cure yet to combat this vicious disease? The word ‘cancer’ is generally used to describe one disease, but the term actually refers to a family of more than 250 different diseases.

St Gallen Breast Cancer Conference

Over the last 15 years, our knowledge of breast cancer has evolved. Availability of targeted treatments and diagnostics has substantially improved the survival for patients with advanced breast cancer.

DNA stands for Diversity Network Associations

While deoxyribonucleic acid, or DNA, is at the core of all created life, recombinant DNA technology was the groundbreaking technology at the origin of Genentech, one of the first biotech companies in the world, founded in 1976.

Driving "state of the art" forward in breast cancer treatment: An interview

This week, an expected 7,500 breast cancer clinicians and researchers from 90 countries will converge on San Antonio, Texas, for the 38th Annual San Antonio Breast Cancer Symposium (SABCS), the worlds largest breast cancer congress.

Roche at 2014 World Cancer Congress (WCC)

The World Cancer Congress (WCC) is an important event for anyone involved in cancer control.

A leap forward for cancer diagnostics

In modern medicine, it is surprising to find that some diagnostic technologies are stuck in the 1970s. In the anatomic pathology lab, outdated processes can expose technicians and patients to potential dangers including tissue cross contamination and misdiagnosis.

Evolving treatment landscape in breast cancer: leaps and hurdles

Since the first known description of breast cancer was written in an Ancient Egyptian text over 3,500 years ago and until the modern age, breast cancer has been known as a disease with no cure.

The value of added sugar

Roche experts have developed a patented method for enzyme production. It enhances the production process for therapeutic antibodies.

Breast cancer: Know more

Despite the significant progress made over the last few decades in patient outcomes, breast cancer is still the most common cancer affecting women.

ESMO acknowledges Roche at 2014 congress

Roche was honoured by the European Society for Medical Oncology (ESMO) during the Presidents session at this weeks ESMO congress in Madrid.

Precise imaging for precision medicine

Cancer is a complex disease that begins when abnormal cells in any part of the body start to grow out of control, forming tumors that behave almost like new organs with their own immune cells and blood vessels.

An interview with Dietmar Berger about personalised medicine

The ESMO theme is very much in line with our focus at Roche, where we are developing targeted medicines based on a deep understanding of molecular pathways and clinical practice.

Roche at the European Society for Medical Oncology Annual Meeting

The ESMO Annual Meeting is one of the largest medical congresses in the world, with over 17,000 physicians expected to attend.

Rising to the global challenge of Alzheimer's Disease

Alzheimers disease, the most common form of dementia, can destroy memory and thinking skills as the condition progresses.

Biosimilars: Not quite the same

It has been a busy time in the world of biosimilars. While regulatory bodies are getting their heads around developing clear-cut rules to ensure the safe introduction of biosimilar monoclonal antibodies, some countries are already seeing the first of these medicines enter the market.

Data sharing: Striking a balance

In response to a societal trend toward greater access to information about medicines, Roche is implementing new ways to share data from its clinical trials.

Depth and diversity at the Fair

More than 500 colleagues from around the world participated in this inaugural fair held at the Mannheim site in mid-May.

Drawn to Science: Clinical trials

Clinical trials are essential to providing the scientific data to determine whether new drugs, diagnostics or procedures are both safe and effective when used to diagnose and treat people.

Big Data - Revealing the unseen

At Roche, we use 18big data19 as an umbrella term for methods and technologies that enable us to process vast amounts of data,1d says Simon Ulrich, Head of Business Intelligence & Master Data Management in Pharma Informatics.

Roche Biochemical Pathways

The Biochemical Pathways Wall Charts have enjoyed worldwide popularity as a standard reference for nearly 50 years.

Talking about accessing external innovation at Roche

At Roche we were one of the first companies to recognise the importance of external innovation.

A long life entirely devoted to science

Every single seat in the large auditorium in Building 71 was occupied at 10.30 a.m. on 22 January, as Nobel laureate Susumu Tonegawa took the podium to give a lecture on the Neuroscience of Memory.

The oncology challenge keeps growing

These numbers are getting to be a huge challenge and the world needs to find ways to tackle the disease.

Roche at ASCO

Investing in tomorrow's leading scientists

The world is facing a general shortfall in oncology scientists and clinicians in the future, and the Academic Relations & Collaborations (ARC) group at Roche is investing in the future careers of the next generation of medical professionals.

What's the prognosis for diagnostic testing in lung cancer?

Being able to test biopsy tissue for all of the targeted therapies being developed is rapidly becoming a significant practical challenge - Roche Group is working on innovative solutions.

Keeping cancer immunotherapy personal

Fighting cancer using patients own immune system is a concept that has been around for a long time, and real advances in our understanding about how to do this have been made over the last 10-15 years.

Testing times for personalised healthcare

A recent survey suggests that awareness of personalised healthcare and its implications for healthcare systems is not universal among all stakeholders

Pioneering healthcare site for those with lung cancer

When people connect online they are able to explore the very latest developments in cancer care and treatment. And for many people with advanced lung cancer, this exchange can offer a sense of comfort and reassurance.

Little all-rounders hit the big time

The Roche Penzberg Antibody Powerhouse delivers highly specific antibodies to the Groups business areas.

Talking about organ donation and transplantation at Roche

Head of Swisstransplant Dr. Franz Immer and Roche General Counsel Dr. Gottlieb Keller talking about organ donation and transplantation.

First ever International School of Biomedical Diagnostics launched

Arizona State University (ASU) and Dublin City University (DCU), Dublin, Ireland are joining forces to create the new International School of Biomedical Diagnostics, which will offer the first degree program of its kind. The initiative is at the cutting edge of establishing diagnostics as an independent discipline.

Personalised healthcare inconceivable without biomarkers

In addition to promoting an exchange of expertise, the main goal of the Oncology Biomarker Symposium was to grow a network across functions, divisions and geographic sites. Biomarker tests can only parallel drug development and, ideally, be launched alongside treatments if Pharmaceuticals and Diagnostics work closely together.

Roche at the American Association for Cancer Research (AACR)

Harnessing Breakthroughs, Targeting Cures is the theme for this years American Association for Cancer Research (AACR) meeting, taking place 5  9 April. AACR highlights the great progress being made by the translation of discoveries in the lab into ground breaking targeted treatments.

What does Alice in Wonderland have to do with research

As a research environment, Switzerland is in good shape. But the take-home message from a star-studded conference on the state of Swiss research is that this is absolutely no excuse to rest on our laurels.

Preparing the next generation

Roche Basel invests a great deal in its apprentices and in their future. But who are the people behind this commitment? We went to find out at a thank-you event for vocational instructors.

At our model shop, special parts are produced to order

If you think that the model shop at Roche Rotkreuz is where you can find models to strut down the runway, youre barking up the wrong tree. The models you see in the Rotkreuz model shop are not at all the catwalk type but rather machines of all sizes producing all manner of noise. Around the shop, workers can be seen fully concentrated on machining a workpiece, though the nine large milling machines almost seem to do the job on their own.

Extracting value from the data deluge

Data galore: Every second, an estimated 3.7 million email messages are sent on a global scale, and every day 4.5 billion like clicks are registered on Facebook.

One foot in the future

On the morning of June 11, numerous Senior Business Leaders gathered in Building 9 in Rotkreuz to marvel at and discuss some IT developments that seem downright futuristic. Demonstrations and role play were used to present new technologies that could one day give the Diagnostics business a competitive edge. When participants were asked to vote on which of these developments they felt should be pursued further, two came right at the top of the list: augmented reality and predictive maintenance. Augmented reality involves extending the perception of reality with the aid of computers, while predictive maintenance is a technique that uses intelligent algorithms to evaluate specific instrument parameters and identify potential malfunctions before they even occur.